Methotrexate pre-filled autoinjector pen (Nordimet®) for subcutaneous injection: a profile of its use in the EU
- 80 Downloads
Nordimet® subcutaneous methotrexate pre-filled autoinjector pens are approved for use in adults with rheumatoid arthritis, severe psoriasis, and psoriatic arthritis, as well as in children and adolescents with severe juvenile idiopathic arthritis. Subcutaneous administration of methotrexate may have advantages for some patients in terms of clinical outcomes relative to oral methotrexate because of its higher level of bioavailability, better clinical efficacy and potentially fewer gastrointestinal adverse effects. The Nordimet® pre-filled autoinjector pen was ergonomically designed to enable self-injection, even for those with compromised manual dexterity, and to improve patient comfort, convenience and safety. Self-injection is accomplished in two easy steps and studies indicate that the device is intuitive to use, with a high level of acceptance, usability and satisfaction.
The manuscript was reviewed by: Renske Hebing, Amsterdam Rheumatology and Immunology Center, Reade Rheumatology, Amsterdam, the Netherlands; Anthony Thaniyan, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia. During the peer review process, Nordic Group BV, the marketing-authorization holder of Nordimet®, was offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with ethical standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
K. McKeage and K.A. Lyseng-Williamson are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.
- 4.Manalo IF, Gilbert KE, Wu JJ. Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis: safety, efficacy, and patient acceptability. Psoriasis Targ Ther. 2015;5:65–70.Google Scholar
- 7.Nordimet solution for injection in pre-filled pen and prefilled syringe: summary of product characteristics. London: European Medicines Agency; 2017.Google Scholar
- 9.Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥ 15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73(8):1549–51.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58(1):73–81.CrossRefPubMedGoogle Scholar
- 14.Fitzpatrick R, Scott DG, Keary I. Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate. Clin Rheumatol. 2013;32(11):1605–12.CrossRefPubMedGoogle Scholar
- 15.Pharma Nordic. Normidet® (injectable methotrexate) monograph. Hoofddorp: Nordic Pharma; 2017.Google Scholar